Today: 27 June 2026
Beazley share price slips as Zurich takeover clock ticks and big holders disclose stakes
10 February 2026
1 min read

Beazley share price slips as Zurich takeover clock ticks and big holders disclose stakes

London, Feb 10, 2026, 09:08 GMT — Regular session

  • Beazley slipped 0.48% to 1,239 pence early in the London session.
  • Shares remain under the 1,335 pence per share figure Zurich has put forward.
  • Vanguard and Norges Bank turned up in the latest UK Takeover Code filings, which flagged both firms’ positions.

Shares of Beazley slipped 0.48% to 1,239 pence by 08:53 GMT on Tuesday, following a Monday close at 1,245 pence. The FTSE 100 insurer started the session at 1,241 pence.

The move itself is modest. Timing, though, draws attention. Investors continue to measure the stock against the takeover timeline. New disclosures are sharpening the view of the shareholder base as the register settles.

Zurich Insurance is weighing a potential cash bid for Beazley, putting a price tag on the company of as much as 1,335 pence per share. That breaks down as 1,310 pence in cash, plus up to 25 pence in dividends permitted for the year through Dec. 31, 2025. As of Tuesday, Beazley’s stock sits about 96 pence, or 7%, below that top-line figure.

Zurich is pushing for a binding offer, following Beazley’s signal that it would likely back the proposal if Zurich goes firm. MKI Global CEO Mark Kelly, speaking last week, put it plainly: “risks should be low” for the deal’s completion. Reuters

Vanguard disclosed a 5.03% stake in Beazley, holding 30,137,865 shares, according to a Form 8.3 filed Monday during the offer period.

Norges Bank’s latest filing, released early Tuesday, puts its stake at 13,995,208 shares, or 2.33%. The bank also picked up a modest 11,928 shares at 12.39 pounds apiece.

Investors hit the 1% threshold in relevant securities during an offer period? The UK Takeover Code says they need to file a Form 8.3. These filings also log any dealing activity, so the market can track positions as the takeover unfolds.

The offer has put a spotlight on other specialty insurers trading in London with ties to Lloyd’s. “Softening pricing across key commercial classes typically sets the stage for a multi‑year consolidation cycle,” Salman Siddiqui, associate managing director at Moody’s Ratings, told Reuters last week. Reuters

Yet Beazley’s shares continue to trade at a discount, underscoring that nothing is sealed just yet. Zurich has until 5:00 p.m. London time on Feb. 16, 2026, to make a firm offer or back out—unless the Takeover Panel grants more time. According to Zurich’s Jan. 19 filing, it already owns roughly 1.465% of Beazley.

Traders now face a period heavy on filings and disclosures, less on big headlines; they’re watching for fresh details around the “put up or shut up” date, and scanning for any trouble spots due diligence might flag.

Aside from the focus on the bid structure, investors have Beazley’s schedule in their sights. Full-year 2025 results land on March 4—timing that could prove pivotal for the permitted dividend language in the existing offer.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

27 June 2026
Lucid surged 15.6% Friday, adding $312 million in equity value—almost double the $158 million in annualized savings from this week’s restructuring plan that cut 18% of its U.S. workforce. Friday’s volume equaled 54% of reported short interest, but the rally outpaced cost-cutting fundamentals, leaving less room for further gains based solely on headcount cuts.
Court ruling on student loans hits private lenders’ health grad loan push

Court ruling on student loans hits private lenders’ health grad loan push

27 June 2026
Judge blocks narrow “professional degree” rule, letting more health-care grad students keep higher federal loan caps; $7.87B in 2023-24 borrowing above new limits remains in federal market, trimming but not eliminating the $4.5B-$5B annual private loan growth Sallie Mae projected from Grad PLUS loan cuts.
US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Previous Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop